# DUTCH Weight Control in Atrial Fibrillation Study

Study · id `cardio:ct-nct06184633` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06184633](<https://clinicaltrials.gov/study/NCT06184633>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06184633

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 280 participants.

## Technical summary

Registry record NCT06184633. Randomized; triple masking; primary purpose treatment. Start 2024-07-21 (actual); primary completion 2027-04-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 280 participants (planned count; ClinicalTrials.gov record NCT06184633, source copy `cardio:ctgov-nct06184633-2026-10-01`, retrieved 2026-10-26)
- Started: 2024-07-21 (actual) (ClinicalTrials.gov record NCT06184633, source copy `cardio:ctgov-nct06184633-2026-10-01`, retrieved 2026-10-26)
- Primary completion: 2027-04-10 (anticipated) (ClinicalTrials.gov record NCT06184633, source copy `cardio:ctgov-nct06184633-2026-10-01`, retrieved 2026-10-26)
- Completion: 2027-05-01 (anticipated) (ClinicalTrials.gov record NCT06184633, source copy `cardio:ctgov-nct06184633-2026-10-01`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT06184633, source copy `cardio:ctgov-nct06184633-2026-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06184633-2026-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: DUTCH Weight Control in Atrial Fibrillation Study
- Acronym: DUTCH-WAIST
- Condition: Atrial Fibrillation
- Condition: Obesity
- Condition: Weight Loss
- Intervention (Drug): Semaglutide 3.2 MG/ML
- Intervention (Drug): Placebo
- Lead sponsor: Rijnstate Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Rijnstate Hospital (`cardio:org-rijnstate-hospital`)

## Provenance

Content hash: cdefc81cb36ac2d5002f214d5b8c6aee168e5d0fe6a5cd457fe103dddeb5fb41
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
